By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.


August 5, 2013


Founders: : Hans Bishop, Richard Klausner, and Robert Nelsen

CEO and Co-founder: Hans Bishop


Please click here for job opportunities.


Please click here for clinical trial information.


Key Statistics

Ownership: Private

Web Site: Juno
Employees: n/a
Symbol: JUNO


Company News
Juno (JUNO) Facing Class Action Lawsuit Following Patient Deaths 8/17/2016 6:57:58 AM
Juno (JUNO) Reports Second Quarter 2016 Financial Results 8/5/2016 10:51:33 AM
Juno (JUNO) Announces Multiple Myeloma Partnership With Memorial Sloan-Kettering Cancer Center And Eureka Therapeutics For Developing CAR T Cell Immunotherapy Against Multiple Novel Targets 8/5/2016 10:17:53 AM
Should Juno (JUNO)'s Trial Troubles Be A Warning To All CAR-T Researchers? 8/1/2016 7:28:31 AM
Juno (JUNO) To Report Second Quarter 2016 Financial Results On Thursday, August 4 7/29/2016 8:36:48 AM
Juno (JUNO) Inks $10 Million + Milestones Deal for Boston's RedoxTherapies to Gain Access to One Molecule 7/14/2016 6:41:15 PM
Juno (JUNO) Stock Falls Again After Correcting Number of Trial Deaths 7/14/2016 6:38:46 PM
Life Science Job Market in Washington State Heats Up as Juno (JUNO) and Seattle Genetics (SGEN) Hire 250+ 7/14/2016 5:59:37 AM
Juno (JUNO) Soars After the FDA OKs Restart of Clinical Trial 7/13/2016 5:45:43 AM
In Juno (JUNO) Patient Deaths, Echoes Seen Of Earlier Failed Company Dendreon (DNDN) 7/11/2016 8:12:35 AM